# CG Oncology Shares Rise About 9% After Phase 3 Bladder Cancer Data

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/58611
Published: 2026-11-16T16:41:19.000Z
Updated: 2026-11-16T16:41:19.000Z
Section: Business

> The data involved cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.

CG Oncology shares rose about 9% in Monday morning trading after the company posted Phase 3 data showing a statistically significant improvement in bladder cancer recurrence risk.

The data covered cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.


